Sandoz Breaks Off Digital Deal With Pear

Decision Follows Change In Sandoz Leadership

Sandoz has announced that partner Pear Therapeutics will now market alone the reSET and reSET-O digital therapeutics launched by the pair in the US almost a year ago. The move follows Richard Saynor taking charge of Sandoz as part of the Novartis unit’s current transformation.

Pear
Pear will market the prescription digital therapeutics alone • Source: Shutterstock

Sandoz and Pear Therapeutics have announced that Pear will now market alone the reSET and reSET-O digital therapeutics for treating substance use disorder and opioid use disorder that the pair launched in the US almost a year ago.

Under a collaboration deal originally struck by Sandoz and Pear in April 2018, Sandoz had said it would “commercialize and...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business